Biomarkers such as reduced cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), increased cortical Aβ plaques or CSF tau levels, temporoparietal 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) hypometabolism, and medial temporal atrophy structures have been reported to be encompassed criteria contributing to MCI-AD diagnosis. Here, MAPT is linked to Alzheimer disease.